Altamira Therapeutics Ltd. (NASDAQ:CYTO) shares are trading higher Thursday after the company announced highlights from its NASAR clinical trial with Bentrio nasal spray were published in video format on the social media channels of the allergology journal, "Allergy."
The Details:
Altamira's NASAR trial enrolled 100 patients who were randomized at a 1:1 ratio to receive either Bentrio or saline nasal spray. The study met its primary efficacy endpoint, showing a statistically significant reduction in the mean daily reflective Total Nasal Symptom Score (rTNSS), as well as its secondary efficacy endpoints.
“We are delighted to see the great results from the NASAR trial shared by Allergy, one the leading medical ...